公开(公告)号：US20070280964A1

公开(公告)日：2007-12-06

申请号：US11805813

申请日：2007-05-24

Applicant: Ruth Knorr ,  Christoph Cavadini ,  Jalil Benyacoub ,  Ebenezer Satyaraj

Inventor： Ruth Knorr ,  Christoph Cavadini ,  Jalil Benyacoub ,  Ebenezer Satyaraj

IPC: A61K39/02 ,  A61K35/74 ,  A61P27/02 ,  A61P31/22

CPC classification number: A61K39/245 ,  A23K10/18 ,  A23K50/48 ,  A61K39/12 ,  A61K39/125 ,  A61K39/23 ,  A61K2039/5254 ,  A61K2039/54 ,  A61K2039/552 ,  A61K2039/55511 ,  A61K2039/70 ,  C12N2710/16034 ,  C12N2750/14034 ,  C12N2770/16034

Abstract: Compositions and methods useful for modulating immunity, enhancing vaccine efficacy, decreasing morbidity associated with chronic FHV-1 infections, and/or preventing or treating conjunctivitis in animals. The compositions contain effective amounts of probiotic Enterococcus bacteria and the methods involve administering such compositions to animals alone, in supplements, or in food compositions in amounts suitable for the intended purpose. In certain embodiments, the probiotic is Enterococcus faecium strain NCIMB 10415 (SF68) and the animal is a feline.

Abstract translation: 用于调节免疫力，增强疫苗功效，降低与慢性FHV-1感染相关的发病率和/或预防或治疗动物结膜炎的组合物和方法。 所述组合物含有有效量的益生菌肠球菌，并且所述方法包括将这些组合物单独施用于动物，补充剂或食物组合物中，适用于预期目的的量。 在某些实施方案中，益生菌是屎肠球菌菌株NCIMB 10415（SF68），动物是猫科动物。

公开(公告)号：US20060160101A1

公开(公告)日：2006-07-20

申请号：US11038682

申请日：2005-01-19

Applicant: Herve Poulet ,  Denis Barral

Inventor： Herve Poulet ,  Denis Barral

IPC: C12Q1/70 ,  C12Q1/68

CPC classification number: A61K39/118 ,  A61K38/00 ,  A61K39/12 ,  A61K39/125 ,  A61K2039/522 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/552 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/16663 ,  C12N2710/16734 ,  C12N2710/24043 ,  C12N2740/13034 ,  C12N2750/14034 ,  C12N2750/14063 ,  C12N2770/16034 ,  C12N2770/16063

Abstract: The present invention relates to improved inactivated feline calicivirus (FCV) vaccines. The invention also provides a process for producing stabilized inactivated FCV, and the use of such stabilized inactivated FCV, in the production of FCV immunogenic compositions. The invention further provides methods of inducing an immune response in an animal of the Felidae family, preferably a cat, using the immunogenic compositions according to the invention.

公开(公告)号：US20040137599A1

公开(公告)日：2004-07-15

申请号：US10471300

申请日：2003-09-08

Inventor： Norman Spibey

IPC: A61K039/275 ,  A61K039/285 ,  C12N007/00

CPC classification number: A61K39/275 ,  A61K39/12 ,  A61K39/125 ,  A61K39/21 ,  A61K39/23 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/552 ,  C12N15/86 ,  C12N2710/24034 ,  C12N2710/24043 ,  C12N2740/13034 ,  C12N2750/14034 ,  C12N2770/16034

Abstract: The present invention is directed to the use of a live, recombinant leporipox virus comprising exogenous DNA, which is operably linked to at least one expression control element and which is incorporated in a non-essential region of the virus genome, in the manufacture of a vector vaccine for the treatment and/or prophylaxis of infectious diseases in non-lepori species. The invention furthermore relates to a live, recombinant leporipox virus comprising exogenous DNA operably linked to at least one expression control element and incorporated in a non-essential region of the virus genome characterized in that said exogenous DNA encodes at least one antigen of a non-lepori pathogen. Due to its restricted host-range the recombinant leporipox virus is non-pathogenic in non-susceptible hosts such as non-lepori vertebrates. Vaccination with said recombinant leporipox virus induced an antigen or immunogenic response in the vaccinated non-lepori host even though productive replication of the virus was not observed in the host.

Abstract translation: 本发明涉及包含外源DNA的活的重组leporipox病毒的用途，所述外源DNA可操作地连接至至少一种表达控制元件，并且其结合到病毒基因组的非必需区域中，用于制备 用于治疗和/或预防非球孢属物种中的传染病的载体疫苗。 本发明还涉及一种活的重组leporipox病毒，其包含与至少一种表达控制元件可操作地连接并并入病毒基因组的非必需区域的外源DNA，其特征在于，所述外源DNA编码至少一种非 - 细菌病原体 由于其宿主范围受限，重组leporipox病毒在非敏感宿主如非细菌脊椎动物中是非致病性的。 使用所述重组leporipox病毒接种疫苗在非接种疫苗的宿主中诱导抗原或免疫原性反应，尽管在宿主中没有观察到病毒的生产性复制。

公开(公告)号：US20150037355A1

公开(公告)日：2015-02-05

申请号：US13978113

申请日：2012-01-04

Applicant: David Kirn ,  John Bell ,  Caroline Breitback ,  Anne Moon ,  Tae-Ho Hwang ,  Yu Kyoung Lee ,  Mi-kyung Kim

Inventor： David Kirn ,  John Bell ,  Caroline Breitback ,  Anne Moon ,  Tae-Ho Hwang ,  Yu Kyoung Lee ,  Mi-kyung Kim

IPC: A61K39/285 ,  A61K39/12 ,  A61K39/145 ,  A61K39/165 ,  A61K39/17 ,  A61K39/125 ,  A61K39/205 ,  A61K39/245 ,  A61K39/235 ,  A61K35/26 ,  G01N33/574 ,  C07K16/18 ,  A61K45/06 ,  C12N7/00 ,  A61K39/395

CPC classification number: A61K39/285 ,  A61K35/26 ,  A61K35/76 ,  A61K35/761 ,  A61K35/763 ,  A61K35/768 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/125 ,  A61K39/145 ,  A61K39/165 ,  A61K39/17 ,  A61K39/205 ,  A61K39/235 ,  A61K39/245 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/55522 ,  C07K16/18 ,  C07K16/30 ,  C07K2317/14 ,  C07K2317/734 ,  C12N7/00 ,  C12N2710/10034 ,  C12N2710/16632 ,  C12N2710/16634 ,  C12N2710/24034 ,  C12N2710/24132 ,  C12N2720/12232 ,  C12N2750/14034 ,  C12N2760/16034 ,  C12N2760/18134 ,  C12N2760/18434 ,  C12N2760/18734 ,  C12N2760/20034 ,  C12N2760/20232 ,  C12N2770/32034 ,  C12N2770/32334 ,  C12N2770/36034 ,  G01N33/574

Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.

Abstract translation: 本发明涉及用于在具有肿瘤的动物中诱导肿瘤特异性抗体介导的补体依赖性细胞毒性应答的方法和组合物，所述方法和组合物包括向所述动物施用包含可复制的溶瘤病毒的组合物，其中组合物在动物中的诱导 产生介导对所述肿瘤特异性的CDC反应的抗体。

公开(公告)号：US20140170180A1

公开(公告)日：2014-06-19

申请号：US13796621

申请日：2013-03-12

Applicant: Arun V. IYER ,  Dianna M. Murphy JORDAN ,  Abby Rae PATTERSON ,  Michael B. ROOF ,  Eric Martin VAUGHN ,  Joseph Gilbert VICTORIA ,  Callie Ann VISEK

Inventor： Arun V. IYER ,  Dianna M. Murphy JORDAN ,  Abby Rae PATTERSON ,  Michael B. ROOF ,  Eric Martin VAUGHN ,  Joseph Gilbert VICTORIA ,  Callie Ann VISEK

IPC: A61K39/23 ,  G01N33/68

CPC classification number: A61K39/23 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/552 ,  C07K14/005 ,  C12N7/00 ,  C12N2750/14021 ,  C12N2750/14022 ,  C12N2750/14034 ,  G01N33/6893

Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.

Abstract translation: 本发明提供新颖的核苷酸序列，蛋白质序列，免疫原性组合物，疫苗以及涉及制造和使用感染尤其是家猪的新型猪细小病毒5A（PPV5A）的方法。 组合物和方法提供了用于检测所述新病毒的感染，监测野生和家畜和猪群中的病毒序列的遗传变化，以及制备和使用新型疫苗以保护动物免受病毒感染。

公开(公告)号：US20140056942A1

公开(公告)日：2014-02-27

申请号：US13967847

申请日：2013-08-15

Applicant: Zhisong Qiao ,  Kevin O'Connell

Inventor： Zhisong Qiao ,  Kevin O'Connell

IPC: A61K47/42 ,  A61K39/155 ,  A61K39/175 ,  A61K47/10 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K39/23 ,  A61K39/235

CPC classification number: A61K39/235 ,  A61K9/08 ,  A61K39/0225 ,  A61K39/12 ,  A61K39/145 ,  A61K39/155 ,  A61K39/175 ,  A61K39/23 ,  A61K47/10 ,  A61K47/183 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K47/42 ,  A61K2039/521 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/552 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/10034 ,  C12N2750/14034 ,  C12N2750/14322 ,  C12N2760/18034 ,  C12N2760/18434 ,  C12N2760/18634

Abstract: The present invention discloses liquid stable vaccines that comprise a live attenuated virus, 10-30% sugar additive, and an amino acid. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.

Abstract translation: 本发明公开了包含活减毒病毒，10-30％糖添加剂和氨基酸的液体稳定疫苗。 本发明还公开了通过这种疫苗的施用来制备这种疫苗和保护动物的方法。

公开(公告)号：US20100041023A9

公开(公告)日：2010-02-18

申请号：US11038682

申请日：2005-01-19

Applicant: Herve Poulet ,  Denis Barral

Inventor： Herve Poulet ,  Denis Barral

IPC: C12Q1/70 ,  C12Q1/68

CPC classification number: A61K39/118 ,  A61K38/00 ,  A61K39/12 ,  A61K39/125 ,  A61K2039/522 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/552 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/16663 ,  C12N2710/16734 ,  C12N2710/24043 ,  C12N2740/13034 ,  C12N2750/14034 ,  C12N2750/14063 ,  C12N2770/16034 ,  C12N2770/16063

Abstract: The present invention relates to improved inactivated feline calicivirus (FCV) vaccines. The invention also provides a process for producing stabilized inactivated FCV, and the use of such stabilized inactivated FCV, in the production of FCV immunogenic compositions. The invention further provides methods of inducing an immune response in an animal of the Felidae family, preferably a cat, using the immunogenic compositions according to the invention.

Abstract translation: 本发明涉及改进的灭活的猫杯状病毒（FCV）疫苗。 本发明还提供了在制备FCV免疫原性组合物中制备稳定的灭活FCV的方法和使用这种稳定的灭活的FCV。 本发明进一步提供使用本发明的免疫原性组合物在猫科动物中诱导免疫应答的方法，优选猫。

公开(公告)号：US20100028379A1

公开(公告)日：2010-02-04

申请号：US12521148

申请日：2007-11-23

Applicant: Cassius M. Tucker ,  John David Haworth

Inventor： Cassius M. Tucker ,  John David Haworth

IPC: A61K39/295 ,  A61K39/175 ,  A61K39/23 ,  A61K39/155 ,  A61K39/215 ,  A61K39/02 ,  A61K39/10 ,  A61P31/12 ,  A61P31/04

CPC classification number: A61K39/235 ,  A61K39/00 ,  A61K39/0225 ,  A61K39/099 ,  A61K39/12 ,  A61K39/155 ,  A61K39/175 ,  A61K39/23 ,  A61K2039/525 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/545 ,  A61K2039/552 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/10034 ,  C12N2710/10071 ,  C12N2710/10334 ,  C12N2750/14034 ,  C12N2750/14071 ,  C12N2750/14334 ,  C12N2760/18034 ,  C12N2760/18071 ,  C12N2760/18434 ,  C12N2760/18471 ,  C12N2770/20022

Abstract: This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.

Abstract translation: 本发明涉及一种治疗狗疾病的方法，包括向狗施用治疗有效量的疫苗，其中所述疫苗包含病毒抗原，菌苗或两者，并且其中所述疫苗根据所述疫苗皮下或口服给药 这里提供的时间表。

公开(公告)号：US20090010963A1

公开(公告)日：2009-01-08

申请号：US12128296

申请日：2008-05-28

Applicant: Stephen Qitu Wu ,  Michael A. Gill ,  Hsien-Jue Chu

Inventor： Stephen Qitu Wu ,  Michael A. Gill ,  Hsien-Jue Chu

IPC: A61K39/00 ,  C12N15/00 ,  C12P19/34 ,  A61P31/00

CPC classification number: A61K39/205 ,  A61K39/0225 ,  A61K39/12 ,  A61K2039/521 ,  A61K2039/5252 ,  A61K2039/5256 ,  A61K2039/552 ,  A61K2039/55566 ,  A61K2039/70 ,  C12N15/86 ,  C12N2710/10334 ,  C12N2710/24143 ,  C12N2750/14034 ,  C12N2760/18434 ,  C12N2760/18734 ,  C12N2760/20134 ,  C12N2770/20034

Abstract: The present invention relates to recombinant raccoon poxvirus vectors that express the rabies virus glycoprotein gene at the hemagglutinin (ha) locus of the poxvirus genome or express the glycoprotein gene of the same or different rabies strains at the thymidine kinase (tk) and the hemagglutinin (ha) loci of the poxvirus genome, and their use as adjuvant-free vaccines. The raccoon poxvirus vector comprises the nucleic acid molecules encoding the glycoprotein of a Challenge Virus Standard rabies strain inserted and expressed at the tk locus of the poxvirus genome and of a Pasteur-Paris rabies strain inserted and expressed at the ha locus of the poxvirus genome. The vaccine may optionally contain a mixture of additional feline and canine antigens for immunization of animals. Also disclosed are methods for inducing an immune response to rabies in a mammal by administering to the mammal an effective immunizing amount of the vaccine of the invention.

Abstract translation: 本发明涉及在痘病毒基因组的血凝素（ha）位点处表达狂犬病毒糖蛋白基因的重组浣熊痘病毒载体，或表达胸苷激酶（tk）和血凝素（tk）上相同或不同狂犬病毒株的糖蛋白基因 ha）痘病毒基因组的基因座，以及它们作为无佐剂疫苗的用途。 浣熊痘病毒载体包含编码在痘病毒基因组的tk基因座插入和表达的挑战病毒标准狂犬病毒株的糖蛋白的核酸分子和在痘病毒基因组的ha位点插入和表达的巴斯德 - 巴黎狂犬病毒株。 疫苗可以任选地含有用于免疫动物的另外的猫科动物和犬抗原的混合物。 还公开了通过向哺乳动物施用有效免疫量的本发明的疫苗来诱导对哺乳动物的狂犬病免疫应答的方法。

公开(公告)号：US20080311151A1

公开(公告)日：2008-12-18

申请号：US12119136

申请日：2008-05-12

Applicant: John Morgan Hardham ,  Kendall Wayne King ,  Rajendra Krishnan ,  Kimberly Jean Dreier ,  David Ross McGavin ,  John David Haworth

Inventor： John Morgan Hardham ,  Kendall Wayne King ,  Rajendra Krishnan ,  Kimberly Jean Dreier ,  David Ross McGavin ,  John David Haworth

IPC: A61K39/295 ,  A61K39/04 ,  A61P31/12 ,  A61P31/04

CPC classification number: A61K39/0216 ,  A61K39/0208 ,  A61K39/12 ,  A61K39/155 ,  A61K39/175 ,  A61K39/215 ,  A61K39/23 ,  A61K39/235 ,  A61K2039/521 ,  A61K2039/552 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/70 ,  C07K14/195 ,  C12N2710/10034 ,  C12N2750/14034 ,  C12N2760/18434 ,  C12N2760/18634 ,  C12N2770/16034

Abstract: The present invention relates to novel bacterial isolates identified by their 16S rRNA DNA, that cause periodontal disease in companion animals, polynucleotide sequences contained therein, polypeptides encoded by such polynucleotide sequences and vaccines comprising such bacteria, polynucleotides, or polypeptides. Also provided are methods for treating and preventing periodontal disease and kits for detecting and treating periodontal disease kits for detecting and preventing periodontal disease. In addition, methods for assessing the efficacy of a vaccine against periodontal diseases in an animal are provided.

Abstract translation: 本发明涉及通过其16S rRNA DNA鉴定的新的细菌分离物，其引起伴侣动物中的牙周病，其中包含的多核苷酸序列，由该多核苷酸序列编码的多肽和包含此类细菌，多核苷酸或多肽的疫苗。 还提供了用于治疗和预防牙周病的方法和用于检测和治疗牙周病试剂盒的试剂盒，用于检测和预防牙周病。 另外，提供了用于评估疫苗针对动物牙周病的功效的方法。